A four-marker panel comprising CSTA, S100A7, MMP9 and SERPINA10 predicted endometrial cancer with an AUC of 0.84 (0.77–0.92), sensitivity of 72.2%, specificity of 87.8%, NPV of 86.7% and PPV of 74.1% (Fig. 3a). This evidence concerns the gene S100A7 and endometrial cancer.